JP2013522589A5 - - Google Patents

Download PDF

Info

Publication number
JP2013522589A5
JP2013522589A5 JP2012556645A JP2012556645A JP2013522589A5 JP 2013522589 A5 JP2013522589 A5 JP 2013522589A5 JP 2012556645 A JP2012556645 A JP 2012556645A JP 2012556645 A JP2012556645 A JP 2012556645A JP 2013522589 A5 JP2013522589 A5 JP 2013522589A5
Authority
JP
Japan
Prior art keywords
cells
cd11b
lin
level
als
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012556645A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013522589A (ja
JP5904953B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IL2011/000227 external-priority patent/WO2011111043A1/en
Publication of JP2013522589A publication Critical patent/JP2013522589A/ja
Publication of JP2013522589A5 publication Critical patent/JP2013522589A5/ja
Application granted granted Critical
Publication of JP5904953B2 publication Critical patent/JP5904953B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012556645A 2010-03-10 2011-03-10 Alsの早期診断およびals進行のための細胞性血液マーカー Expired - Fee Related JP5904953B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31233510P 2010-03-10 2010-03-10
US61/312,335 2010-03-10
PCT/IL2011/000227 WO2011111043A1 (en) 2010-03-10 2011-03-10 Cellular blood markers for early diagnosis of als and for als progression

Publications (3)

Publication Number Publication Date
JP2013522589A JP2013522589A (ja) 2013-06-13
JP2013522589A5 true JP2013522589A5 (https=) 2014-04-24
JP5904953B2 JP5904953B2 (ja) 2016-04-20

Family

ID=43971347

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012556645A Expired - Fee Related JP5904953B2 (ja) 2010-03-10 2011-03-10 Alsの早期診断およびals進行のための細胞性血液マーカー

Country Status (5)

Country Link
US (2) US20130230499A1 (https=)
EP (1) EP2545381A1 (https=)
JP (1) JP5904953B2 (https=)
CA (1) CA2792471A1 (https=)
WO (1) WO2011111043A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013144957A1 (en) 2012-03-26 2013-10-03 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Cellular markers for diagnosis of alzheimer's disease and for alzheimer's disease progression
JP7012384B2 (ja) 2017-06-27 2022-02-14 ニューラクル サイエンス カンパニー リミテッド 癌治療のための抗fam19a5抗体の用途
AU2019264996A1 (en) * 2018-05-10 2020-11-26 The Methodist Hospital Methods for prognosis and management of disease
DE102019121344A1 (de) * 2019-08-07 2021-02-11 ToposNomos Ltd. Verfahren und Durchflusszytometer zum Untersuchen einer menschlichen oder tierischen Zellprobe sowie Computerprogrammprodukt
KR20240042044A (ko) 2021-08-09 2024-04-01 뉴로퀘스트 엘티디 전임상 알츠하이머병을 검출하기 위한 조성물, 키트 및 방법
EP4426295A1 (en) * 2021-11-02 2024-09-11 Tranquis Therapeutics, Inc. Selection and treatment of subjects having a circulating myeloid cell inflammatory phenotype
JPWO2025058005A1 (https=) * 2023-09-15 2025-03-20
WO2025263405A1 (ja) * 2024-06-18 2025-12-26 慶應義塾 筋萎縮性側索硬化症における判定、疾患修飾薬治療効果予測および判定、モニタリング、並びに層別化のためのバイオマーカーおよび方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5426028A (en) * 1991-07-05 1995-06-20 Rush-Presbyterian-St. Lukes Medical Center Screening method for chronic immune dysfunction syndrome
US7410773B2 (en) * 1995-02-02 2008-08-12 Ghazi Jaswinder Dhoot Method of preparing an undifferentiated cell
PT1248643E (pt) * 2000-01-20 2005-10-31 Yeda Res & Dev Utilizacao de copolimero 1 e peptidos e polipeptidos congeneres e de celulas t tratadas co estes compostos para terapia neuroprotectora
US20020081635A1 (en) * 2000-05-11 2002-06-27 Thomas Terry E. Novel antibody compositions for preparing enriched T cell preparations
CA2358061A1 (en) * 2000-09-08 2002-03-08 Stemcell Technologies Inc. Novel antibody compositions for the negative selection of specific rat leukocyte subsets
US20030077576A1 (en) * 2001-03-20 2003-04-24 Joann Trial Use of monoclonal antibodies and functional assays for prediction of risk of opportunistic infection
US7030126B2 (en) * 2001-11-16 2006-04-18 Als Therapy Development Foundation, Inc. Use of polyamine analogs for amyotrophic lateral sclerosis
US7105183B2 (en) * 2004-02-03 2006-09-12 The Regents Of The University Of California Chlorite in the treatment of neurodegenerative disease
JP5254017B2 (ja) * 2005-09-12 2013-08-07 カウンシル・オブ・サイエンティフィック・アンド・インダストリアル・リサーチ ビピリジン化合物「セルロマイシンa」、その誘導体および類似体の免疫抑制剤としての使用
WO2007136157A1 (en) * 2006-05-24 2007-11-29 Hee Tae Kim Compositions and methods for treating motor neuron diseases
WO2008036374A2 (en) * 2006-09-21 2008-03-27 Medistem Laboratories, Inc. Allogeneic stem cell transplants in non-conditioned recipients
EP2073009A1 (en) * 2007-12-19 2009-06-24 Cell Med Research GMBH Method for T, NK and NKT cells
US10114012B2 (en) * 2008-10-31 2018-10-30 The Board Of Trustees Of The Leland Stanford Junior University Methods and assays for detecting and quantifying pure subpopulations of white blood cells in immune system disorders
US20120225038A1 (en) * 2009-01-28 2012-09-06 Istituto Oncologico Veneto Myeloid-derived suppressor cells generated in vitro

Similar Documents

Publication Publication Date Title
JP2013522589A5 (https=)
Zhang et al. Linc‐MAF‐4 regulates Th1/Th2 differentiation and is associated with the pathogenesis of multiple sclerosis by targeting MAF
Lakkisto et al. Heme oxygenase-1 and carbon monoxide promote neovascularization after myocardial infarction by modulating the expression of HIF-1α, SDF-1α and VEGF-B
JP2015511721A5 (https=)
WO2009121031A4 (en) Methods of novel therapeutic candidate identification through gene expression analysis in vascular-related diseases
US20190259467A1 (en) Method of predicting graft versus host disease
McDermott et al. Nonrelapse mortality and mycophenolic acid exposure in nonmyeloablative hematopoietic cell transplantation
Zhang et al. Circulating T follicular helper cells are associated with rapid virological response in chronic hepatitis C patients undergoing peginterferon therapy
Drulovic et al. Expression of Th1 and Th17 cytokines and transcription factors in multiple sclerosis patients: does baseline T-bet mRNA predict the response to interferon-beta treatment?
CA2792471A1 (en) Cellular blood markers for early diagnosis of als and for als progression
WO2018234404A1 (en) STRATIFICATION OF PATIENTS WITH ACUTE MYELOID LEUKEMIA FOR SENSITIVITY TO KINASE INHIBITOR THERAPY
JP2012520446A5 (https=)
Sakai et al. Inclusion body myositis with granuloma formation in muscle tissue
Imlay et al. Pathogen‐agnostic immune biomarkers that predict infection after solid organ transplantation
WO2014032899A1 (en) Diagnosis and treatment of lupus nephritis
CN110295228A (zh) 检测gata2的物质在制备诊断活动性结核病的试剂盒中的应用
CA2589279A1 (en) Methods to identify, prepare, and use naive t cell recent thymic emigrants
CN116802320A (zh) 使用细环病毒(ttv)作为确定t淋巴细胞增殖能力的标志
JP2015503106A5 (https=)
Huynh et al. Molecular analysis of immune cell subsets and cytokine profiles in septic Vietnamese patients
EP3396377A1 (en) Cd24hicd38hi transitional b cells and cd9 as new biomarker of long-term human lung allograft survival
Balashov et al. Increased expression of miR-130b-5p in B cells and its modulation by glatiramer acetate in multiple sclerosis
WO2012077983A3 (ko) Ape1/ref-1을 함유하는 방광암 진단용 조성물, 및 이를 이용한 방광암 진단 키트
DHARSHANI V et al. Pattern of Circulating Mesenchymal Stromal Cells and Hematopoietic Progenitor and Stem Cells in the Peripheral Blood of Trauma Patients with and without Hemorrhagic Shock
Sandgren lnduction Therapies in Multiple Sclerosis-Clinical and immunological follow-up